Aesthetic devices maker Ulthera won a new U.S. patent for an ultrasound-based therapy for treating sweat glands disorders, such as hyperhidrosis
The patent, titled "Methods for treatment of sweat glands" was granted by the U.S. Patent & Trademark Office late last week, according to a press release.
"This new patent adds a significant asset to the patent portfolio for Ulthera, which has rights to over 100 U.S. and international patents that are issued, published or pending," president & CEO Matthew Likens said in prepared remarks. "The groundbreaking advances underlying this patent are a result of many years of collaboration between Ulthera and Guided Therapy Systems, LLC, a global innovator of ultrasound-based technology."
Ulthera’s recent study showed that 3% of the general population is "profoundly affected" by hyperhidrosis and many more consider themselves "sweat-bothered," Likens added.
“The potential to treat a medical condition and positively impact a patient’s quality of life is a logical progression for our platform technology," he said.
It’s the 2nd recent win for privately held Arizona-based Ulthera, maker of the 1st ultrasound based technology for non-invasively tightening skin.
Earlier this month Ulthera won FDA clearance for its Ulthera System, an energy-based platform device designed to non-invasively "tighten turkey necks and smooth out double-chins."
On June 4-5, DeviceTalks Minnesota is taking over the Twin Cities medtech industry with one of the most anticipated conferences of the spring.
Join leaders from 3M, Abbott, Bigfoot Biomedical, Boston Scientific, Cardionomic, CMF Solutions, Cyient, Google Mayo Clinic, Medical Alley, Medtronic, NxThera, Opus College, Relievant Medsystems, University of Minnesota, Star Tribune, Smith & Nephew, Spry Health, Zimmer Biomet and many more when you register today.
Use the code "DTWeb" to save 15% on the cost of registration.